Mediolanum International Funds Ltd Lowers Holdings in DexCom, Inc. $DXCM

Mediolanum International Funds Ltd decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 18.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 151,989 shares of the medical device company’s stock after selling 34,918 shares during the period. Mediolanum International Funds Ltd’s holdings in DexCom were worth $9,408,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Reflection Asset Management bought a new stake in DexCom during the 4th quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new position in DexCom in the 1st quarter worth approximately $25,000. CVA Family Office LLC boosted its stake in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. MCF Advisors LLC purchased a new stake in DexCom during the 4th quarter valued at approximately $32,000. Finally, ORG Partners LLC grew its holdings in DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after buying an additional 281 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In other news, EVP Jon Coleman sold 4,912 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $73.00, for a total value of $358,576.00. Following the sale, the executive vice president owned 100,361 shares of the company’s stock, valued at approximately $7,326,353. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,750 shares of company stock valued at $5,163,241 over the last three months. Corporate insiders own 0.28% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on DXCM shares. UBS Group set a $95.00 price objective on shares of DexCom in a research report on Wednesday, June 10th. Truist Financial lifted their price target on shares of DexCom from $80.00 to $87.00 and gave the company a “buy” rating in a report on Thursday. Citigroup reiterated a “buy” rating and issued a $84.00 price target (up from $79.00) on shares of DexCom in a research note on Thursday, May 28th. Stifel Nicolaus set a $90.00 price objective on DexCom and gave the company a “buy” rating in a research report on Friday, June 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $88.00 target price (up from $75.00) on shares of DexCom in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $85.36.

DexCom Price Performance

NASDAQ:DXCM opened at $76.65 on Monday. The firm has a market capitalization of $29.58 billion, a price-to-earnings ratio of 32.76, a PEG ratio of 1.26 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The business has a 50 day simple moving average of $71.16 and a 200-day simple moving average of $68.74. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the company posted $0.32 EPS. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. Equities analysts forecast that DexCom, Inc. will post 2.57 EPS for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.